Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells [0.03%]
CURCUMIN衍生物HO-3867联合Olaparib在输卵管上皮细胞转化中的协同作用研究
Cai-Chieh Tseng,Min-Hsi Ku,Wei-Min Wu et al.
Cai-Chieh Tseng et al.
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to high recurrence rates and treatment-related toxicities. Although PARP inhibitors like Olaparib have shown efficacy in BRCA-mutated cancers, their benefit...
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia [0.03%]
HOXA9直接功能竞争性抑制剂与表观遗传学抑制剂对MLL基因重排急性髓系白血病模型细胞增殖、凋亡和分化过程的影响机制研究
Julie Vrevin,Mélanie Lambert,Marine Andrique et al.
Julie Vrevin et al.
Recent progress in cancer treatment has led to the development of advanced therapies targeting specific oncogenic drivers, with, for instance, new small molecule-targeted agents, antibody-drug conjugates, peptide drugs, cell-based, or gene ...
Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report [0.03%]
帕博西尼联合氟维司群治疗终末期肾病行血液透析的激素受体阳性人表皮生长因子受体2阴性转移性乳腺癌患者的药代动力学、疗效及安全性：1例报告
Toshiaki Takakura,Tsutomu Iwasa,Chiyo K Imamura et al.
Toshiaki Takakura et al.
Palbociclib combined with fulvestrant is a standard treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) -negative metastatic breast cancer. Both agents are mainly eliminated by hepatic metabolism, and it...
Clinical features, treatment and outcomes of dabrafenib-associated uveitis [0.03%]
达拉菲尼相关性葡萄膜炎的临床特征、治疗及转归分析
Jieqiong Liu,Wei Sun,Chunjiang Wang
Jieqiong Liu
Background: To explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment. Methods: ...
Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer [0.03%]
工程化外泌体递送si-HER2与曲妥珠单抗治疗HER2阳性胃癌的比较研究分析
Yuehong Zhu,Yaoyang Guo,Ziyi Dong et al.
Yuehong Zhu et al.
Trastuzumab is currently a key targeted drug for HER2-positive gastric cancer (GC), but there are common problems of drug resistance and cardiotoxicity in clinical treatment, resulting in poor therapeutic effects. Exosomes are natural nanoc...
Design and optimization of PLGA-based gemcitabine nanocapsule for enhanced pancreatic cancer efficacy [0.03%]
基于PLGA的吉西他滨纳米囊泡的设计与优化以增强其抗癌疗效
Gaurav Tiwari,Satyajit Panda,A Salomy Monica Diyya et al.
Gaurav Tiwari et al.
This study aimed to develop gemcitabine-loaded nanocapsules for pancreatic cancer treatment, optimizing their formulation before evaluating them through in vivo studies. The researchers selected gemcitabine as the model drug because it has ...
Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin [0.03%]
日本罕见儿科疾病药物开发的挑战及异维A酸案例研究
Shota Inoue,Akihiko Ozaki,Hayase Hakariya et al.
Shota Inoue et al.
Drug lag in rare pediatric diseases remains a significant challenge in Japan despite its sophisticated healthcare system. We examined this issue through a case study of isotretinoin, an established standard drug for high-risk neuroblastoma ...
Low-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis [0.03%]
低剂量PD-1抑制在复发/难治性经典霍奇金淋巴瘤中的应用：系统评价和meta分析
Mobil Akhmedov,Pervin Zeynalova,Alexander Fedenko et al.
Mobil Akhmedov et al.
Introduction: No correlation between the dose, adverse events, and efficacy was detected in clinical trials of anti-PD-1 antibodies across a range of solid and hematological malignancies. Given that dose reduction with po...
Safety and pharmacokinetics of FCN-437c, a novel cyclin-dependent kinase 4/6 inhibitor, in Chinese patients with hepatic impairment [0.03%]
FCN-437c（一种新型细胞周期蛋白依赖性激酶4/6抑制剂）在中国肝功能不全患者中的安全性与药动学研究
Jia Xu,Jingrui Liu,Yanhua Ding et al.
Jia Xu et al.
This study explored the impact of hepatic impairment on the safety and pharmacokinetics (PK) of FCN-437c, a novel dual CDK4/6 inhibitor for potential breast cancer treatment. In an open-label trial, 25 subjects (8 with mild hepatic impairme...
Targeting neuroblastoma with hydroxamic acid based HDAC1 and HDAC2 inhibitors: Insights from in vitro and in vivo studies [0.03%]
基于羟胺类组蛋白去乙酰化酶HDAC1/2抑制剂的神经母细胞瘤靶向治疗：来自体内外研究的启示
Padmini Pai,Yashaswini Reddy,Ipshita Das et al.
Padmini Pai et al.
Histone deacetylases (HDACs) serve a crucial function in transcription regulation, and their dysregulation is linked to numerous diseases, including cancer. Among them, HDAC1 and HDAC2 are particularly significant in neural progenitors and ...